Rhumbline Advisers Purchases Shares of 45,519 ChromaDex Co. (NASDAQ:CDXC)

Rhumbline Advisers acquired a new stake in ChromaDex Co. (NASDAQ:CDXC) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 45,519 shares of the company’s stock, valued at approximately $124,000. Rhumbline Advisers owned 0.06% of ChromaDex as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bank of New York Mellon Corp lifted its stake in ChromaDex by 170.0% in the second quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company’s stock valued at $520,000 after buying an additional 119,915 shares during the period. Perritt Capital Management Inc. bought a new position in shares of ChromaDex in the first quarter valued at approximately $139,000. Acadian Asset Management LLC bought a new stake in ChromaDex in the 1st quarter worth about $67,000. SG Americas Securities LLC bought a new stake in ChromaDex in the 1st quarter worth about $54,000. Finally, Lazard Asset Management LLC purchased a new stake in ChromaDex in the 1st quarter valued at about $43,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

Insiders Place Their Bets

In other news, Director Kristin Patrick sold 23,000 shares of the stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $3.57, for a total value of $82,110.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 9.64% of the company’s stock.

ChromaDex Stock Performance

CDXC stock opened at $3.65 on Tuesday. The stock has a fifty day moving average of $3.27 and a 200-day moving average of $3.23. The company has a market capitalization of $275.72 million, a price-to-earnings ratio of -73.00 and a beta of 1.86. ChromaDex Co. has a fifty-two week low of $1.25 and a fifty-two week high of $4.65.

Analysts Set New Price Targets

Several research firms have weighed in on CDXC. HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of ChromaDex in a research report on Friday, August 9th. Roth Mkm restated a “buy” rating and set a $6.00 price target on shares of ChromaDex in a research report on Wednesday, June 12th.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.